under conditions sufficient to provide a substantially monodispersed mixture comprising polymers having the structure of Formula III:

$$R^2(OC_2H_4)_{m+n}—OR^1 \quad \text{(III);}$$

activating the substantially monodispersed mixture comprising polymers of Formula III to provide a substantially monodispersed mixture of activated polymers capable of reacting with a drug; and

reacting the substantially monodispersed mixture of activated polymers with a drug under conditions sufficient to provide a substantially monodispersed mixture of conjugates each comprising a drug coupled to an oligomer that comprises a polyethylene glycol moiety with m+n subunits.

73. The process according to claim **68**, further comprising:

reacting a substantially monodispersed mixture comprising compounds having the structure of Formula IV:

$$R^1(OC_2H_4)_n—OH \quad \text{(IV)}$$

under conditions sufficient to provide a substantially monodispersed mixture comprising compounds having the structure of Formula I:

$$R^1(OC_2H_4)_n—O^-X^+ \quad \text{(I).}$$

74. The process according to claim **68**, wherein the activating of the substantially monodispersed mixture comprises reacting the substantially monodispersed mixture of polymers of Formula III with N-hydroxy succinimide to provide an activated polymer capable of reacting with a drug.

75. The process according to claim **68**, wherein the drug is a polypeptide, and wherein the reacting of the substantially monodispersed mixture of activated polymers with a substantially monodispersed mixture of polypeptides comprises:

reacting the substantially monodispersed mixture of activated polymers with one or more amino functionalities of the polypeptide to provide a substantially monodispersed mixture of conjugates each comprising the polypeptide coupled to an oligomer that comprises a polyethylene glycol moiety with m+n subunits.

* * * * *